Enterprise record

Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinica

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:9c84e695-b238-43e3-8559-a8c7fa2dba63Version: public-1As of: unavailable

13 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 5 claims
    • Legal Name: Eledon Pharmaceuticals, Inc. · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 28, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 28, 2026

  2. Eledon Pharmaceuticals, Inc. DEF 14A 2025-04-29

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 28, 2026

    Supports 8 claims
    • Leadership Role: Allan D. Kirk, M.D., Ph.D., FACS: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: David-Alexandre C. Gros, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: James Robinson: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Jan Hillson, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: John S. McBride: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: June Lee, M.D.: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Keith A. Katkin: Director · Claim reviewed: Sep 28, 2026
    • Leadership Role: Steven Perrin, Ph.D.: Director · Claim reviewed: Sep 28, 2026